Albumin-drug interaction and its clinical implication

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 12, 2013, Pages 5435-5443

  Yamasaki, Keishi ^a   Chuang, Victor Tuan Giam ^b   Maruyama, Toru ^c   Otagiri, Masaki ^a  

^a SOJO UNIVERSITY   (Japan)

^b CURTIN UNIVERSITY   (Australia)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Binding site; Displacement; Extracorporeal albumin dialysis; Human serum albumin; Structure function relationship

Indexed keywords

EID: 84885375036     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2013.05.005     Document Type: Review

References (125)

1. T. Peters Jr. All About Albumin: Biochemistry, Genetics, and Medical Applications 1996 Academic Press San Diego
2. G. Fanali, V. Trezza, M. Marino, M. Fasano, and P. Ascenzi Human serum albumin: from bench to bedside Mol. Aspects Med. 33 2012 209 290
3. U. Kragh-Hansen, V.T.G. Chuang, and M. Otagiri Practical aspects of the ligand-binding and enzymatic properties of human serum albumin Biol. Pharm. Bull. 25 2002 695 704 (Pubitemid 40036701)
4. J.R. Simard, P.A. Zunszain, C.E. Ha, J.S. Yang, N.V. Bhagavan, I. Petitpas, S. Curry, and J.A. Hamilton Locating high-affinity fatty acid-binding sites on albumin by X-ray crystallography and NMR spectroscopy Proc. Natl. Acad. Sci. U. S. A. 102 2005 17958 17963 (Pubitemid 41798484)
5. M. Otagiri A molecular functional study on the interactions of drugs with plasma proteins Drug Metab. Pharmacokinet. 20 2005 309 323
6. J. Ghuman, P.a Zunszain, I. Petitpas, A.A. Bhattacharya, M. Otagiri, and S. Curry Structural basis of the drug-binding specificity of human serum albumin J. Mol. Biol. 353 2005 38 52 (Pubitemid 41338838)
7. M. Rowland, and T.N. Tozer Clinical Pharmacokinetics and Pharmacodynamics - Concepts and Applications fourth ed. 2010 Lippincott Williams & Wilkins Philadelphia
8. J. Koch-Weser, and E.M. Sellers Binding of drugs to serum albumin (first of two parts) N. Engl. J. Med. 294 1976 311 316
9. D.A. Smith, L. Di, and E.H. Kerns The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nat. Rev. Drug Discov. 9 2010 929 939
10. J.J. Vallner Binding of drugs by albumin and plasma protein J. Pharm. Sci. 66 1977 447 465
11. M.C. Meyer, and D.E. Guttman The binding of drugs by plasma proteins J. Pharm. Sci. 57 1968 895 918
12. W.J. Jusko, and M. Gretch Plasma and tissue protein binding of drugs in pharmacokinetics Drug Metab. Rev. 5 1976 43 140
13. S. Curry Lessons from the crystallographic analysis of small molecule binding to human serum albumin Drug Metab. Pharmacokinet. 24 2009 342 357
14. D.C. Carter, and J.X. Ho Structure of serum albumin Adv. Protein Chem. 45 1994 153 203 (Pubitemid 24139888)
15. J.J. MacKichan Influence of protein binding and use of unbound (free) drug concentrations M.E. Burton, L.M. Shaw, J.J. Schentag, W.E. Evans, Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring fourth ed. 2005 Lippincott Williams & Wilkins Philadelphia 82 120
16. S. Curry, H. Mandelkow, P. Brick, and N. Franks Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites Nat. Struct. Biol. 5 1998 827 835 (Pubitemid 28402087)
17. S. Sugio, A. Kashima, S. Mochizuki, M. Noda, and K. Kobayashi Crystal structure of human serum albumin at 2.5 A resolution Protein Eng. 12 1999 439 446 (Pubitemid 29322441)
18. G. Sudlow, D.J. Birkett, and D.N. Wade The characterization of two specific drug binding sites on human serum albumin Mol. Pharmacol. 11 1975 824 832
19. G. Sudlow, D.J. Birkett, and D.N. Wade Further characterization of specific drug binding sites on human serum albumin Mol. Pharmacol. 12 1976 1052 1061
20. O.J. Bos, J.P. Remijn, M.J. Fischer, J. Wilting, and L.H. Janssen Location and characterization of the warfarin binding site of human serum albumin - a comparative study of two large fragments Biochem. Pharmacol. 37 1988 3905 3909
21. O.J. Bos, M.J. Fischer, J. Wilting, and L.H. Janssen Drug-binding and other physicochemical properties of a large tryptic and a large peptic fragment of human serum albumin Biochim. Biophys. Acta 953 1988 37 47 (Pubitemid 18051926)
22. S. Curry X-ray crystallography of albumin M. Otagiri, Human Serum Albumin - New Insights on its Structural Dynamics, Functional Impacts and Pharmaceutical Applications 2011 Sojo University Publishing Center Kumamoto 1 29
23. K.J. Fehske, E. Jähnchen, W.E. Müller, and A. Stillbauer Azapropazone binding to human serum albumin Naunyn Schmiedebergs Arch. Pharmacol. 313 1980 159 163 (Pubitemid 10055858)
24. K.J. Fehske, U. Schläfer, U. Wollert, and W.E. Müller Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone Mol. Pharmacol. 21 1982 387 393 (Pubitemid 12139839)
25. K.J. Fehske, W.E. Müller, and U. Wollert The location of drug binding sites in human serum albumin Biochem. Pharmacol. 30 1981 687 692 (Pubitemid 11146814)
26. K. Yamasaki, T. Maruyama, U. Kragh-Hansen, and M. Otagiri Characterization of site I on human serum albumin: concept about the structure of a drug binding site Biochim. Biophys. Acta 1295 1996 147 157 (Pubitemid 26233243)
27. U. Kragh-Hansen Relations between high-affinity binding sites for l-tryptophan, diazepam, salicylate and phenol red on human serum albumin Biochem. J. 209 1983 135 142
28. U. Kragh-Hansen Relations between high-affinity binding sites of markers for binding regions on human serum albumin Biochem. J. 225 1985 629 638 (Pubitemid 15174251)
29. U. Kragh-Hansen Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands Mol. Pharmacol. 34 1988 160 171
30. K. Yamasaki, T. Maruyama, A. Takadate, A. Suenaga, U. Kragh-Hansen, and M. Otagiri Characterization of site I of human serum albumin using spectroscopic analyses: locational relations between regions Ib and Ic of site I J. Pharm. Sci. 93 2004 3004 3012 (Pubitemid 39657804)
31. L. Zhu, F. Yang, L. Chen, E.J. Meehan, and M. Huang A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography J. Struct. Biol. 162 2008 40 49
32. I. Petitpas, A.A. Bhattacharya, S. Twine, M. East, and S. Curry Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I J. Biol. Chem. 276 2001 22804 22809
33. S. Wanwimolruk, D.J. Birkett, and P.M. Brooks Structural requirements for drug binding to site II on human serum albumin Mol. Pharmacol. 24 1983 458 463 (Pubitemid 14249842)
34. T. Itoh, Y. Saura, Y. Tsuda, and H. Yamada Stereoselectivity and enantiomer-enantiomer interactions in the binding of ibuprofen to human serum albumin Chirality 9 1997 643 649 (Pubitemid 27479370)
35. V.T. Chuang, and M. Otagiri Flunitrazepam, a 7-nitro-1,4-benzodiazepine that is unable to bind to the indole-benzodiazepine site of human serum albumin Biochim. Biophys. Acta 1546 2001 337 345 (Pubitemid 32280829)
36. A.J. Ryan, C.-W. Chung, and S. Curry Crystallographic analysis reveals the structural basis of the high-affinity binding of iophenoxic acid to human serum albumin BMC Struct. Biol. 11 2011 18
37. A.A. Bhattacharya, T. Grüne, and S. Curry Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin J. Mol. Biol. 303 2000 721 732
38. I. Sjöholm, B. Ekman, A. Kober, I. Ljungstedt-Påhlman, B. Seiving, and T. Sjödin Binding of drugs to human serum albumin: XI. The specificity of three binding sites as studied with albumin immobilized in microparticles Mol. Pharmacol. 16 1979 767 777
39. A.A. Bhattacharya, S. Curry, and N.P. Franks Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures J. Biol. Chem. 275 2000 38731 38738 (Pubitemid 32009208)
40. P.A. Zunszain, J. Ghuman, A.F. McDonagh, and S. Curry Crystallographic analysis of human serum albumin complexed with 4Z, 15E-bilirubin-IXα J. Mol. Biol. 381 2008 394 406
41. K.L. Hein, U. Kragh-Hansen, J.P. Morth, M.D. Jeppesen, D. Otzen, J.V. Møller, and P. Nissen Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin J. Struct. Biol. 171 2010 353 360
42. K. Oettl, and R.E. Stauber Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties Br. J. Pharmacol. 151 2007 580 590 (Pubitemid 47016287)
43. R. Narazaki, M. Hamada, K. Harada, and M. Otagiri Covalent binding between bucillamine derivatives and human serum albumin Pharm. Res. 13 1996 1317 1321 (Pubitemid 26344974)
44. J. Christodoulou, P.J. Sadler, and S. Tucker Gold-induced structural switch of cys34 in albumin: comparison of auranofin with aurothiomalate Metal-Based Drugs 1 1994 527
45. D.A. Keire, S.V. Mariappan, J. Peng, and D.L. Rabenstein Nuclear magnetic resonance studies of the binding of captopril and penicillamine by serum albumin Biochem. Pharmacol. 46 1993 1059 1069 (Pubitemid 23280548)
46. R. Narazaki, K. Harada, A. Sugii, and M. Otagiri Kinetic analysis of the covalent binding of captopril to human serum albumin J. Pharm. Sci. 86 1997 215 219 (Pubitemid 27078387)
47. C. Bertucci, B. Nanni, A. Raffaelli, and P. Salvadori Chemical modification of human albumin at cys34 by ethacrynic acid: structural characterisation and binding properties J. Pharm. Biomed. Anal. 18 1998 127 136 (Pubitemid 28529329)
48. A.I. Ivanov, J. Christodoulou, J.A. Parkinson, K.J. Barnham, A. Tucker, J. Woodrow, and P.J. Sadler Cisplatin binding sites on human albumin J. Biol. Chem. 273 1998 14721 14730 (Pubitemid 28272756)
49. D. Noort, A.G. Hulst, and R. Jansen Covalent binding of nitrogen mustards to the cysteine-34 residue in human serum albumin Arch. Toxicol. 76 2002 83 88 (Pubitemid 34251559)
50. M.C. Damsten, J.N.M. Commandeur, A. Fidder, A.G. Hulst, D. Touw, D. Noort, and N.P.E. Vermeulen Liquid chromatography/tandem mass spectrometry detection of covalent binding of acetaminophen to human serum albumin Drug Metab. Dispos. 35 2007 1408 1417 (Pubitemid 47121783)
51. D.A. Joyce, R.O. Day, and B.R. Murphy The pharmacokinetics of albumin conjugates of d-penicillamine in humans Drug Metab. Dispos. 19 1991 309 311
52. R. Narazaki, and M. Otagiri Covalent binding of a bucillamine derivative with albumin in sera from healthy subjects and patients with various diseases Pharm. Res. 14 1997 351 353 (Pubitemid 27160948)
53. M.T. Montero, R. Pouplana, O. Valls, and S. García On the binding of cinmetacin and indomethacin to human serum albumin J. Pharm. Pharmacol. 38 1986 925 927 (Pubitemid 17200298)
54. N. Takamura, T. Maruyama, E. Chosa, K. Kawai, Y. Tsutsumi, Y. Uryu, K. Yamasaki, T. Deguchi, and M. Otagiri Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome Drug Metab. Dispos. 33 2005 596 602 (Pubitemid 40393204)
55. A.H. Anton Drug-protein binding. IV. Modulation of binding Increasing activity of sulfonamides with displacing agents: a review Ann. N. Y. Acad. Sci. 226 1973 273 292
56. R.K. Verbeeck, A. Boel, A. Buntinx, and P.J. De Schepper Plasma protein binding and interaction studies with diflunisal, a new salicylate analgesic Biochem. Pharmacol. 29 1980 571 576 (Pubitemid 10212897)
57. V.T. Chuang, A. Kuniyasu, H. Nakayama, Y. Matsushita, S. Hirono, and M. Otagiri Helix 6 of subdomain III A of human serum albumin is the region primarily photolabeled by ketoprofen, an arylpropionic acid NSAID containing a benzophenone moiety Biochim. Biophys. Acta 1434 1999 18 30 (Pubitemid 29521329)
58. B. Honoré, and R. Brodersen Albumin binding of anti-inflammatory drugs Utility of a site-oriented versus a stoichiometric analysis Mol. Pharmacol. 25 1984 137 150 (Pubitemid 14223264)
59. N. Setoguchi, N. Takamura, K. Fujita, K. Ogata, J. Tokunaga, T. Nishio, E. Chosa, K. Arimori, K. Kawai, and R. Yamamoto A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis Biopharm. Drug Dispos. 2012 10.1002/bdd.1829
60. I. Mignot, N. Presle, F. Lapicque, C. Monot, R. Dropsy, and P. Netter Albumin binding sites for etodolac enantiomers Chirality 8 1996 271 280 (Pubitemid 26259331)
61. H. Meisner, and K. Neet Competitive binding of long-chain free fatty acids, octanoate, and chlorophenoxyisobutyrate to albumin Mol. Pharmacol. 14 1978 337 346 (Pubitemid 8305834)
62. P.E. Rolan, and L. Court Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br. J. Clin. Pharmacol. 37 1994 125 128 (Pubitemid 24213753)
63. G. Fanali, A. di Masi, V. Trezza, M. Marino, M. Fasano, and P. Ascenzi Human serum albumin: from bench to bedside Mol. Aspects Med. 33 2012 209 290
64. S. Schmidt, D. Gonzalez, and H. Derendorf Significance of protein binding in pharmacokinetics and pharmacodynamics J. Pharm. Sci. 99 2010 1107 1122
65. P.F. D'Arcy, and J.C. McElnay Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites Pharmacol. Ther. 17 1982 211 220 (Pubitemid 13236429)
66. J. Koch-Weser, and E.M. Sellers Drug therapy. Binding of drugs to serum albumin (second of two parts) N. Engl. J. Med. 294 1976 526 531
67. S.L. Fox Potentiation of anticoagulants caused by pyrazole compounds JAMA 188 1964 320 321
68. P.M. Aggeler, R.A. O'Reilly, L. Leong, and P.E. Kowitz Potentiation of anticoagulant effect of warfarin by phenylbutazone N. Engl. J. Med. 276 1967 496 501
69. S. Harder, and P. Thürmann Clinically important drug interactions with anticoagulants. An update Clin. Pharmacokinet. 30 1996 416 444
70. Y. Hatakeyama, S. Niwano, H. Niwano, T. Kosukegawa, and T. Izumi Risks and benefits of combined use of bucolome and warfarin in anticoagulation therapy Int. Heart J. 51 2010 399 403
71. M. Osawa, N. Hada, K. Matsumoto, T. Hasegawa, D. Kobayashi, Y. Morimoto, M. Yamaguchi, I. Kanamoto, T. Nakagawa, and K. Sugibayashi Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions Int. J. Pharm. 293 2005 43 49 (Pubitemid 40381079)
72. B.B. Brodie Displacement of one drug by another from carrier or receptor sites Proc. R. Soc. Med. 58 1965 946 955
73. J.P. Tillement, R. Zini, C. Mattei, and E. Singlas Effect of phenylbutazone on the binding of vitamin K antagonists to albumin Eur. J. Clin. Pharmacol. 6 1973 15 18
74. H. Abe, M. Sawada, T. Toda, N. Kurosawa, E. Owada, I. Tazawa, and S. Sakuma Evaluation of co-administration of bucolome for warfarin therapy from the view point of protein binding Jpn. J. Ther. Drug Monit. 12 1995 293 298
75. M. Matsuoka Thrombosis therapy Geriatr. Med. 15 1977 505 512
76. A. Majima, T. Hosono, and K. Kawabe A new method of anticoagulant therapy used by combination warfarin and bucolome Niigata Igaku Kai Zasshi 88 1982 95 119
77. J.O. Miners, and D.J. Birkett Cytochrome P4502C9: an enzyme of major importance in human drug metabolism Br. J. Clin. Pharmacol. 45 1998 525 538 (Pubitemid 28270907)
78. H. Takahashi, T. Kashima, S. Kimura, N. Murata, T. Takaba, K. Iwade, T. Abe, H. Tainaka, T. Yasumori, and a H. Echizen Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of in vitro approaches to predicting In vivo reduction of (S)-warfarin clearance Drug Metab. Dispos. 27 1999 1179 1186 (Pubitemid 29463605)
79. S.M. Pond, D.J. Birkett, and D.N. Wade Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole Clin. Pharmacol. Ther. 22 1977 573 579 (Pubitemid 8225573)
80. K. Komatsu, K. Ito, Y. Nakajima, S.I. Kanamitsu, S. Imaoka, Y. Funae, C.E. Green, C.A. Tyson, N. Shimada, and Y. Sugiyama Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments Drug Metab. Dispos. 28 2000 475 481 (Pubitemid 30185687)
81. J. Zi, D. Liu, P. Ma, H. Huang, J. Zhu, D. Wei, J. Yang, and C. Chen Effects of CYP2C93 and CYP2C913 on diclofenac metabolism and inhibition-based drug-drug interactions Drug Metab. Pharmacokinet. 25 2010 343 350
82. K. Ogata, N. Takamura, J. Tokunaga, and K. Kawai Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats J. Pharm. Pharmacol. 60 2008 15 20
83. 123I-iodoamphetamine J. Nucl. Med. 50 2009 1378 1383
84. K. Nishi, M. Kobayashi, R. Nishii, N. Shikano, N. Takamura, and N. Kuga Pharmacokinetic alteration of (99 m)Tc-MAG3 using serum protein binding displacement method Nucl. Med. Biol. 2013 10.1016/j.nucmedbio.2012.12.002
85. R. Gugler, and D.L. Azarnoff Drug protein binding and the nephrotic syndrome Clin. Pharmacokinet. 1 1976 25 35
86. M.M. Reidenberg, and D.E. Drayer Alteration of drug-protein binding in renal disease Clin. Pharmacokinet. 9 Suppl. 1 1984 18 26 (Pubitemid 14179497)
87. A. Dasgupta, and D. Havlik Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin Ther. Drug Monit. 20 1998 658 662 (Pubitemid 28544296)
88. S. Erill, R. Calvo, and R. Carlos Plasma protein carbamylation and decreased acidic drug protein binding in uremia Clin. Pharmacol. Ther. 27 1980 612 618 (Pubitemid 10105592)
89. R. Calvo, R. Carlos, and S. Erill Effects of carbamylation of plasma proteins and competitive displacers on drug binding in uremia Pharmacology 24 1982 248 252 (Pubitemid 12153554)
90. T. Sakai, T. Maruyama, H. Imamura, H. Shimada, and M. Otagiri Mechanism of stereoselective serum binding of ketoprofen after hemodialysis J. Pharmacol. Exp. Ther. 278 1996 786 792 (Pubitemid 27167047)
91. H. Watanabe, Y. Miyamoto, M. Otagiri, and T. Maruyama Update on the pharmacokinetics and redox properties of protein-bound uremic toxins J. Pharm. Sci. 100 2011 3682 3695
92. T. Sakai, A. Takadate, and M. Otagiri Characterization of binding site of uremic toxins on human serum albumin Biol. Pharm. Bull. 18 1995 1755 1761 (Pubitemid 26012996)
93. N. Takamura, T. Maruyama, and M. Otagiri Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia Clin. Chem. 43 1997 2274 2280 (Pubitemid 28022962)
94. K. Mera, M. Anraku, K. Kitamura, K. Nakajou, T. Maruyama, and M. Otagiri The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst Biochem. Biophys. Res. Commun. 334 2005 1322 1328 (Pubitemid 41074719)
95. J.P. Doweiko, and D.J. Nompleggi The role of albumin in human physiology and pathophysiology, Part III: albumin and disease states JPEN J. Parenter. Enteral Nutr. 15 1991 476 483
96. A.H. Lau, L.E. Gustavson, R. Sperelakis, N.P. Lam, T. El-Shourbagy, J.X. Qian, and T. Layden Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function Epilepsia 38 1997 445 451 (Pubitemid 27172025)
97. A. Kober, A. Jenner, and I. Sjöholm Differentiated effects of liver cirrhosis on the albumin binding sites for diazepam, salicylic acid and warfarin Biochem. Pharmacol. 27 1978 2729 2735
98. S. Klammt, S.R. Mitzner, J. Stange, J. Loock, and U. Heemann Improvement of impaired albumin binding capacity in acute-on-chronic liver failure by albumin dialysis Liver Transpl. 14 2008 1333 1339
99. F. Ruiz-Cabello, and S. Erill Abnormal serum protein binding of acidic drugs in diabetes mellitus Clin. Pharmacol. Ther. 36 1984 691 695 (Pubitemid 15224675)
100. J. Baraka-Vidot, A. Guerin-Dubourg, E. Bourdon, and P. Rondeau Impaired drug-binding capacities of in vitro and in vivo glycated albumin Biochimie 94 2012 1960 1967
101. G.D. Anderson, B.E. Gidal, R.J. Hendryx, A.B. Awan, N.R. Temkin, A.J. Wilensky, and H.R. Winn Decreased plasma protein binding of valproate in patients with acute head trauma Br. J. Clin. Pharmacol. 37 1994 559 562 (Pubitemid 24197149)
102. G. Arredondo, R. Calvo, F. Marcos, R. Martínez-Jordá, and E. Suarez Protein binding of itraconazole and fluconazole in patients with cancer Int. J. Clin. Pharmacol. Ther. 33 1995 449 452
103. M.E. Winter Clinical pharmacokinetics L.Y. Young, M.A. Koda-Kimble, Applied Therapeutics: The Clinical Use of Drugs sixth ed. 1998 Applied Therapeutic, Inc. Washington 2-1 2-21
104. M.E. Winter Basic Clinical Pharmacokinetics fourth ed. 2004 Lippincott Williams & Wilkins Philadelphia
105. S.R. Mitzner Extracorporeal liver support-albumin dialysis with the molecular adsorbent recirculating system Ann. Hepatol. 10 2011 S21 S28
106. C.J. Karvellas, S.M. Bagshaw, R.C. McDermid, D.E. Stollery, and R.T. Gibney Acetaminophen-induced acute liver failure treated with single-pass albumin dialysis: report of a case Int. J. Artif. Organs 31 2008 450 455 (Pubitemid 351983359)
107. M. Boyle, J. Kurtovic, D. Bihari, S. Riordan, and C. Steiner Equipment review: the molecular adsorbents recirculating system (MARS) Crit. Care 8 2004 280 286 (Pubitemid 39144718)
108. S.R. Mitzner, J.A.N. Stange, S. Klammt, P. Peszynski, R. Schmidt, and G. Nöldge-schomburg Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure J. Am. Soc. Nephrol. 12 2001 S75 S82
109. A. Kortgen, F. Rauchfuss, M. Götz, U. Settmacher, M. Bauer, and C. Sponholz Albumin dialysis in liver failure: comparison of molecular adsorbent recirculating system and single pass albumin dialysis - a retrospective analysis Ther. Apher. 13 2009 419 425
110. W. Laleman, A. Wilmer, P. Evenepoel, I. Elst, M. Zeegers, Z. Zaman, C. Verslype, J. Fevery, and F. Nevens Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure Crit. Care 10 2006 R108
111. S. Sen, N.A. Davies, R.P. Mookerjee, L.M. Cheshire, S.J. Hodges, R. Williams, and R. Jalan Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study Liver Transpl. 10 2004 1109 1119 (Pubitemid 39248408)
112. J. Stange, S.R. Mitzner, T. Risler, C.M. Erley, W. Lauchart, H. Goehl, S. Klammt, P. Peszynski, J. Freytag, H. Hickstein, M. Löhr, S. Liebe, W. Schareck, U.T. Hopt, and R. Schmidt Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support Artif. Organs 23 1999 319 330 (Pubitemid 29200993)
113. P. Krisper, V. Stadlbauer, and R.E. Stauber Clearing of toxic substances: are there differences between the available liver support devices? Liver Int. 31 2011 5 8
114. S. Mitzner, S. Klammt, J. Stange, and R. Schmidt Albumin regeneration in liver support-comparison of different methods Ther. Apher. Dial. 10 2006 108 117
115. J. Vienken, and H. Christmann How can liver toxins be removed? Filtration and adsorption with the Prometheus system Ther. Apher. Dial. 10 2006 125 131
116. C.J. Karvellas, N. Gibney, D. Kutsogiannis, J. Wendon, and V.G. Bain Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure Crit. Care 11 2007 215
117. G. De Schoenmakere, J. De Waele, W. Terryn, M. Deweweire, A. Verstraete, E. Hoste, S. Rottey, N. Lameire, and F. Colardyn Phenytoin intoxication in critically ill patients Am. J. Kidney Dis. 45 2005 189 192 (Pubitemid 40038060)
118. S. Korsheed, N.M. Selby, and R.J. Fluck Treatment of severe theophylline poisoning with the molecular adsorbent recirculating system (MARS) Nephrol. Dial. Transplant. 22 2007 969 970 (Pubitemid 46351739)
119. S. Sen, N. Ratnaraj, N.A. Davies, R.P. Mookerjee, C.E. Cooper, P.N. Patsalos, R. Williams, and R. Jalan Treatment of phenytoin toxicity by the molecular adsorbents recirculating system (MARS) Epilepsia 44 2003 265 267 (Pubitemid 36206034)
120. A.C. de Pont Extracorporeal treatment of intoxications Curr. Opin. Crit. Care 13 2007 668 673
121. N. Pichon, B. François, C. Chevreuil, and J.M. Gaulier Albumin dialysis: a new therapeutic alternative for severe diltiazem intoxication Clin. Toxicol. (Phila.) 44 2006 195 196 (Pubitemid 44112957)
122. N. Pichon, A. Dugard, M. Clavel, J.B. Amiel, and B. François Extracorporeal albumin dialysis in three cases of acute calcium channel blocker poisoning with life-threatening refractory cardiogenic shock Ann. Emerg. Med. 59 2012 540 544
123. C. Kawasaki, R. Nishi, S. Uekihara, S. Hayano, and M. Otagiri Charcoal hemoperfusion in the treatment of phenytoin overdose Am. J. Kidney Dis. 35 2000 323 326 (Pubitemid 30070858)
124. C.I. Kawasaki, R. Nishi, S. Uekihara, S. Hayano, U. Kragh-Hansen, and M. Otagiri How tightly can a drug be bound to a protein and still be removable by charcoal hemoperfusion in overdose cases? Clin. Toxicol. (Phila.) 43 2005 95 99
125. A. Minomo, Y. Ishima, V.T.G. Chuang, Y. Suwa, U. Kragh-Hansen, T. Narisoko, H. Morioka, T. Maruyama, and M. Otagiri Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment Biochim. Biophys. Acta 2013 1 7